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Gazing into the crystal ball
The recently determined crystal structures of complexes between
bacterial toxin 'superantigens' and MHC class II molecules shed
light on the nature of the interactions between these two molecules.
The term 'superantigen' has been introduced to describe
a group of microbial antigens that interact with an
unusually large proportion of T cells and that differ in
some respects from conventional peptide antigens. The
recognition of superantigens by the T-cell receptor
appears to depend entirely on the variable region of the
T-cell receptor 3 chain (V3), instead of the combination
of all the T-cell receptor's diverse parts - Vot, Jx, V3,
DP, J and N regions - that is required for conven-
tional antigen recognition. As the number of different
V3 genes is limited, a superantigen is capable of interact-
ing with a large fraction (2-25 %) of T cells, whereas the
frequency of reactive cells for a conventional antigen is
usually less than 1 in 1 000. Like peptide antigens, super-
antigens are presented by class II molecules of the major
histocompatibility complex (MHC) but, unlike peptide
antigens, they do not attach via the MHC molecule's
peptide-binding groove.
At present, two types of superantigen are known. The
first type is a protein made by mouse mammary tumor
viruses (MMTVs), retroviruses that in infectious form are
the causative agents of mammary carcinoma. The second
type of superantigen is represented by a growing list of
bacterial and mycoplasma proteins, such as staphylococcus
or streptococcus toxins. Staphylococcus aureus. produces
several enterotoxins - staphylococcal enterotoxins A-E
(SEA-SEE) - which cause food poisoning, as well as
toxic shock syndrome toxin 1 (TSST-1), which has been
implicated in the human toxic shock syndrome. The tox-
icity of bacterial superantigens is thought to be mediated
by their potent T-cell stimulatory activity, which leads to
lymphokine release, increased capillary permeability and
shock. The two types of superantigen are not structurally
related, at least not in their primary protein sequence.
That MMTV superantigens interact directly with MHC
class II molecules has so far only been inferred from
functional data. Thus, the evidence for the interaction
includes the finding that the recognition of MMTV
superantigens can be blocked by anti-class II antibodies
[1]. Furthermore, mice that are I-E- - that is, mice
lacking expression of the MHC class II locus I-E - are
unable to present most of the MMTV superantigens. It is
disappointing that it has not been possible to demonstrate
the association between MMTV superantigens and
MHC class II by co-immunoprecipitation studies.
The interaction between bacterial toxins and MHC class
II proteins has, by contrast, been well characterized. The
dissociation constants for the binding of SEA and
TSST-1 to MHC class II molecules are estimated to be
about 10-7-10-8 M [2,3]. The interaction with MHC
class II molecules appears to involve more than one bind-
ing site and varies among the toxins. Thus, Kappler and
colleagues deduced from their mutational analysis [4] that
SEB has two distinct binding sites for class II molecules.
It has also been shown that SEB and TSST-1 interact
with different sites on the human class II molecule HLA-
DR1, because these two toxins do not compete with
each other for binding to HLA-DR. SEA, on the other
hand, competes with both SEB and TSST-1, indicating
that the toxins bind to separate but overlapping sites on
the MHC class II molecule.
Several MHC class II residues that are important for the
binding of SEA, SEB and TSST-1 have been mapped. All
these residues are on the distal domains of the class II
molecule, close to the region involved in T-cell receptor
binding, but outside the peptide-binding groove. Overall,
the data obtained from mutational studies imply that there
is more than one binding site for an individual toxin, and
that there are distinct sites for different toxins. These sites
appear to involve both the x and 3 chains of MHC class
II molecules, and it is possible that the binding results in
cross-linking of the two chains.
The recent determination, by X-ray crystallography, of
the structures of SEB-DR1 [5] and TSST-1-DR1 [6]
complexes has provided direct insights into these issues
(Fig. la-d). SEB is seen to bind as an intact protein to
the -helical region of the DR1 (x chain, outside
the conventional peptide-binding groove. SEB thus does
not interact directly with the bound antigenic peptide,
and no large conformational changes in the DR1-peptide
complex seem to be induced by simultaneous binding of
SEB. One loop of SEB covers the residues of DR1
recognized by the T-cell receptor in conventional peptide
antigen presentation (Fig. la,c), suggesting an unorthodox
mode of interaction between the SEB-DR1 complex and
the T-cell receptor.
Although TSST-1 and SEB show only 16% sequence
identity, their three-dimensional structures are very simi-
lar. TSST-1 does, however, differ in sequence from SEB
at residues involved in binding to DR1, suggesting that
the two toxins interact with class II differently. This is
demonstrated by the respective crystal structures of their
complexes with DR1. SEB contacts DR1 at two sites,
exclusively on the DR1 ot chain, primarily off one edge of
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Fig. 1. Structures of complexes between HLA-DR1 and the superantigens SEB and TSST-1. (a) Crystal structure of the SEB-DR1
complex. The HLA-DR1 al and 51 domains are blue; the antigenic peptide is yellow; and SEB is red. (b) Crystal structure of the
TSST-1-DR1 complex. The a and P chains of HLA-DR1 are blue; the antigenic peptide is yellow; and TSST-I is orange. (c) Schematic
structure of the SEB-DRI complex, showing the exclusive binding of SEB to the a chain of DR1, primarily off one edge of the peptide-
binding groove. (d) Schematic structure of the TSST-1-DR1 complex, showing how TSST-1 - in contrast to SEB - binds to both a and
[ chains of DR1 and contacts part of the bound peptide. ((a) and (b) modified from [5] and [6], respectively).
the peptide-binding groove (Fig. la,c). The TSST-1 bind-
ing site, on the other hand, extends over almost half of
the peptide-binding site, so that TSST-1 contacts the 
helix of the DR1 a chain, the bound peptide and part of
the ct helix of the DR1 13 chain (Fig. lb,d). This suggests
that TSST-1 binding is likely to be peptide-dependent.
Furthermore, it is likely that the recognition of
TSST-1-DR1 by the T-cell receptor is very different
from that of SEB-DRi or peptide-DR1.
Although no crystal structure of a T-cell receptor has yet
been determined, several models of its three-dimensional
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configuration have been proposed. The Davis and
Bjorkman model [7] predicts that the T-cell receptor
folds, like immunoglobulins, into three 'complementarity-
determining regions' (CDR1-3) that bind to the
peptide-MHC molecule complex. CDR1 and CDR2
interact with the MHC molecule, and CDR3, formed
by the VolJa and V3D3J3 junction, contacts the peptide
in the groove of the MHC molecule. The region of the
T-cell receptor that interacts with a superantigen has
been shown to be a hypervariable loop, HV4, in the V3
domain between strands D and E, corresponding to
residues 67-77 of the human V chain, which is
predicted to form a solvent-exposed face located on one
side of the antigen-binding face [8].
Structural models for T-cell receptor interaction with a
superantigen have been proposed based on mutational
analyses and the three-dimensional configurations of
SEB, TSST-1 and the SEB-DR1 complex [5,9,10].
Direct binding studies of many toxins to class II mol-
ecules suggest that different bacterial toxins contact dis-
tinct regions on the MHC molecule, even though they
all interact directly with the T-cell receptor V chain,
implying that there are many distinct modes of inter-
action between T-cell receptor, superantigen and class II
molecule. The distinct modes of toxin binding to DR1
revealed by the crystallographic studies indicates that the
T-cell receptor may be oriented differently in complexes
with different superantigens. In addition, the fact that
TSST-1 contacts the peptide in the peptide-binding
groove suggests that T-cell activation by certain super-
antigens may be directed by the peptide antigen.
Although very little is known about the recognition of
MMTV superantigens by the T-cell receptor, the residues
on the V3 chain involved in binding viral superantigens
appear to be on the same solvent-exposed face as those
- generally different - residues that are involved in
binding the bacterial toxins. Mutational analysis of the
interaction between V and the Mtv-7 superantigen
showed that the critical amino acids are within the HV4
loop of V3 and an adjacent 3 strand leading up to the
CDR1 loop [11]. Thus, all the available data so far sug-
gest that both bacterial and viral superantigens bind to a
solvent-exposed face on the lateral side of the T-cell
receptor V3 chain, which is distinct from the conven-
tional peptide recognition site.
The recent elucidation of the crystal structures of
SEB-DR1 and TSST-1-DR1 complexes has, therefore,
provided a clear picture of the diversity in of interactions
between toxins and MHC class II molecules [5,6]. The
interesting and surprising findings of the very different
binding modes of these two toxins suggest different ways
of T-cell receptor recognition of superantigens.
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